**Attachment A-1. Process Evaluation of the NIH Roadmap Epigenomics Program (NIDA)**

**Roadmap Epigenomics Program RFA Requirements for Evaluation**

| **RFA Title and Number** | **RFA Requirement for Evaluation** |
| --- | --- |
| **RFA Location** | **RFA Referenced Text** |
| Epigenomics Data Analysis and Coordination Center – EDACC (U01)RFA-RM-07-014 | Part II, Section I.1Evaluation  | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the EDACC, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.” |
|  | Section VI.3Reporting | Periodically, throughout the life of the program, awardees may be required to provide data that can be used to evaluate program progress, such as (but not limited to) the following: * Completion of reference epigenome maps
* Submission of REMCs/EDACCs products to a public database
* Examples of how new technologies (e.g., methods, software) are used
* Examples of innovations
* Collaboration with other Roadmap Epigenomics Program participants (REMCs, NCBI, Technology RFA awardees, demonstration project RFA awardees)
* Multi-REMC/EDACC authored publications
* Communication of EDACC methods and results in a variety of settings
* Adoption of cutting edge methods, algorithms

Such information may be used in evaluations of the EDACC as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. |
| Reference Epigenome Mapping Centers (U01)RFA-RM-07-013 | Part II, Section I.1Evaluation | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the REMCs as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.” |
|  | IV.6. Other Submission Requirements | Applicants must plan to submit progress reports twice per year-once at the time of the non-competing continuation and once at a time to be determined by program staff. Program staff will use information from reports, site visits, etc. to evaluate each grantees progress and the success of the overall program; this information will be used to determine if funding levels should be increased or decreased for future years, for each grant and for the program. Progress will also be evaluated with the assistance of external advisors at the biannual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below). |
| Technology Development in Epigenetics (R01)RFA-RM-07-011 | Part II, Section I.1Evaluation | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Technology Development projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.” |
|  | IV.6. Other Submission Requirements | This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below). |
| Technology Development in Epigenetics (R21)RFA-RM-07-012 | Part II, Section I.1Evaluation | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Technology Development projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.” |
|  | IV.6. Other Submission Requirements | This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below). |
| Epigenomics of Human Health and Disease (R01) RFA-RM-08-017 | Part II. Section I.1.Evaluation | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the initiative as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program mid-course evaluation will be directed by the Roadmap Epigenomics Working Group. Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.” |
|  | Section IV.6Other Submission Requirements | This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Roadmap Epigenomics Program as a whole, NIH staff may need to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual Non-Competing Grant Process Report (PHS 2590, http://grants.nih.gov/grants/funding/2590/2590.htm), awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below). |
| Discovery of Novel Epigenetic Marks in Mammalian Cells (R01)RFA-RM-07-015 | Part II, Section I.1Evaluation | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Epigenetic Mark Discovery projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.” |
|  | Section IV.6Other Submission Requirements | This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below). |
| Discovery of Novel Epigenetic Marks in Mammalian Cells (R21)RFA-RM-07-016 | Part II, Section I.1Evaluation | As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Epigenetic Mark Discovery projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in [Section IV.6.](file:///E%3A%5CEpigen%20Eval%5CDocs%20NIH%5CRFAs%5CRFA%20R21%20Novel%20MARKS%20RFA-RM-07-016.html#SectionIV6) Application and Submission Information, “Other Submission Requirements.” |
|  | Section IV.6Other Submission Requirements | This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below). |